Stock Yards Bank & Trust Co. increased its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 16.5% during the fourth ...

Calamos Advisors LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 33.4% in the fourth quarter, Holdings ...

--"The 2025 forecast will command the most attention in the annual accounts," Hansen said. "The addition of production capacity will continue to be the guiding principle for the full-year forecast." ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.45 which represents a decrease of $-0.89 or -1.04% from the prior close of $85.34. The stock opened at $84.87 and touched a low of $84 ...

Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.03 which represents a decrease of $-1.16 or -1.36% from the prior close of $85.19. The stock opened at $85.62 and touched a low of $83 ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

European shares are trading near their largest discount on record to the S&P 500 index, at a forward price-to-earnings ratio ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...